Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABUS 
Arbutus Biopharma Corp (ABUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ABUS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.26
1 Year Target Price $5.26
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 48.5% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 843.48M USD | Price to earnings Ratio - | 1Y Target Price 5.26 |
Price to earnings Ratio - | 1Y Target Price 5.26 | ||
Volume (30-day avg) 4 | Beta 1.01 | 52 Weeks Range 2.71 - 5.10 | Updated Date 09/17/2025 |
52 Weeks Range 2.71 - 5.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 17.81% |
Management Effectiveness
Return on Assets (TTM) -21.01% | Return on Equity (TTM) -52.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 746475258 | Price to Sales(TTM) 54.71 |
Enterprise Value 746475258 | Price to Sales(TTM) 54.71 | ||
Enterprise Value to Revenue 48.42 | Enterprise Value to EBITDA -5.64 | Shares Outstanding 191699008 | Shares Floating 126049560 |
Shares Outstanding 191699008 | Shares Floating 126049560 | ||
Percent Insiders 21.87 | Percent Institutions 62.59 |
Upturn AI SWOT
Arbutus Biopharma Corp
Company Overview
History and Background
Arbutus Biopharma Corp, founded in 2003 as Tekmira Pharmaceuticals, focuses on developing novel therapeutics for chronic hepatitis B virus (HBV) infection. They have evolved through acquisitions and strategic shifts, focusing primarily on HBV cure research.
Core Business Areas
- HBV Therapeutics: Development of RNA interference therapeutics, capsid inhibitors, and other modalities for HBV infection. Their pipeline includes clinical-stage and preclinical assets.
Leadership and Structure
The leadership team includes a CEO, CSO, and CFO, along with a board of directors. The organizational structure is typical for a biotechnology company, with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- AB-729: An RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg) expression. AB-729 is currently the lead asset being developed to address HBV infection. Market share data is not applicable as the product is still in clinical trials. Competitors include Vir Biotechnology (VIR), Assembly Biosciences (ASMB) and Dicerna Pharmaceuticals, now part of Novo Nordisk.
Market Dynamics
Industry Overview
The hepatitis B treatment market is driven by the global prevalence of chronic HBV infection and the need for more effective therapies. The market includes existing treatments and emerging novel approaches aimed at functional cure.
Positioning
Arbutus Biopharma Corp is positioned as a company focused on developing a functional cure for HBV through novel mechanisms, including RNAi and capsid inhibition. Competitive advantages include their deep understanding of HBV biology and their innovative therapeutic platforms.
Total Addressable Market (TAM)
The global hepatitis B therapeutics market is projected to reach billions of dollars. Arbutus Biopharma is targeting a significant portion of this market by developing a functional cure.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in HBV biology
- Proprietary technology platforms (RNAi, capsid inhibitors)
- Promising clinical trial data for AB-729
- Experienced management team
Weaknesses
- Dependence on a limited number of pipeline assets
- High research and development costs
- Regulatory and clinical trial risks
- Reliance on financing to fund operations
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal discovery or acquisition
- Positive clinical trial outcomes leading to regulatory approval
- Advancements in HBV treatment landscape
Threats
- Competition from other HBV drug developers
- Clinical trial failures
- Regulatory hurdles
- Market access challenges
- Patent expiration
Competitors and Market Share
Key Competitors
- VIR
- ASMB
- NVO
Competitive Landscape
Arbutus faces intense competition from larger pharmaceutical companies and other biotechnology companies developing HBV therapies. Their advantage lies in their novel technology and focused expertise.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing its HBV pipeline and securing collaborations.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its HBV therapies.
Recent Initiatives: Recent initiatives include advancing AB-729 through clinical trials and expanding its pipeline with new therapeutic candidates.
Summary
Arbutus Biopharma is a biotech company laser-focused on a cure for Hepatitis B with a few promising treatments in their pipeline. They face typical biotech risks like regulatory uncertainty and intense competition. Success hinges on positive clinical trial results, which should lead to partnering opportunities and market share. With their high risk comes the potential for high reward, and the company has experienced leadership focused on the HBV cure market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is approximate and subject to change. Investment decisions should be made based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquaters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.arbutusbio.com |
Full time employees 44 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.